Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression-Reference-Cited by-同舟云学术

Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression

Published:2022-03-21 Issue:1 Volume:11 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Jeon Donghwan¹,McNeel Douglas G.¹

Affiliation:

1. University of Wisconsin Carbone Cancer Center, Madison, WI, USA

Funder

NIH

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2022.2054758

Reference57 articles.

1. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

2. The Upregulation of LAG-3 on T Cells Defines a Subpopulation with Functional Exhaustion and Correlates with Disease Progression in HIV-Infected Subjects

3. CD160-Associated CD8 T-Cell Functional Impairment Is Independent of PD-1 Expression

4. VISTA: A novel immunotherapy target for normalizing innate and adaptive immunity

5. TIGIT as an emerging immune checkpoint

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JAML promotes the antitumor role of tumor-resident CD8+ T cells by facilitating their innate-like function in human lung cancer;Cancer Letters;2024-05

2. Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy;Journal for ImmunoTherapy of Cancer;2024-05

3. Toll-like receptor agonists as cancer vaccine adjuvants;Human Vaccines & Immunotherapeutics;2023-12-28

4. Quantifying the impact of immunotherapy on RNA dynamics in cancer;Journal for ImmunoTherapy of Cancer;2023-11

5. A syngeneic spontaneous zebrafish model oftp53-deficient, EGFR^viii, and PI3KCA^H1047R-driven glioblastoma reveals inhibitory roles for inflammation during tumor initiation and relapsein vivo;2023-10-20